Based on our findings, we speculated that patients with ccRCC harbouring the WT PBRM1 gene and a high E27 inclusion in the PBRM1 pre-mRNA may expect greater therapeutic effects from everolimus treatment than from nivolumab treatment. This evidence concerns the gene PBRM1 and nonpapillary renal cell carcinoma.